The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 20 insertion mutations. The appearance of exon 20 insertions is a common resistance mechanism to earlier generations of EGFR inhibitors including [...]
TAK-788: an EGFR Exon 20 Insertion Mutant (EGFRex20ins) Inhibitor for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Takeda EGFRex20 Inhibitor
EGFR exon 20 mutant inhibitor, oral once-daily Breakthrough Therapy for ex20+ NSCLC (Ph. I) from cellular screening + SBDD mobocertinib ARIAD/Takeda, Cambridge, MA
Loading...
